Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.
about
The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T CellsGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineBooster dose after 10 years is recommended following 17DD-YF primary vaccinationImmune activation alters cellular and humoral responses to yellow fever 17D vaccineLive Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern DayLack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus InfectionPrevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adultsAdaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccinationVaccination strategies against Zika virusT Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal ModelsScreening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotypeHow advances in immunology provide insight into improving vaccine efficacy.Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015.Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in miceMathematical modeling provides kinetic details of the human immune response to vaccination.Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive AntibodiesA Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after VaccinationImmunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and MaliUpdate on Zika Diagnostic Tests and WHO's Related ActivitiesA randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months oldEnveloped virus-like particles as vaccines against pathogenic arboviruses.Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate.Current status and future prospects of yellow fever vaccines.Human T Cell Memory: A Dynamic ViewEnquiries to the United Kingdom National Travel Advice Line by healthcare professionals regarding immunocompromised travellers.A Meta-Analysis of Serological Response Associated with Yellow Fever Vaccination.A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.Dengue Virus: Protection by T Cells, Disease Exacerbation by Antibodies?[New aspects in travel vaccinations].[Vaccinations and prophylaxis: what to consider].The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences.Yellow Fever in an Unvaccinated Traveler to Peru.Current concerns and perspectives on Zika virus co-infection with arboviruses and HIV.Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community.Determinants of red blood cell alloantibody detection duration: analysis of multiply alloimmunized patients supports peritransfusion factors.Late or Lack of Vaccination Linked to Importation of Yellow Fever from Angola to China.Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.
P2860
Q26700099-F1D9932F-0FA4-4C4D-B7A1-4ADC72D4A928Q26782367-00FED099-4EB9-4064-BF02-F15537316C7FQ27468573-03AEA6BD-5A7D-44CD-9912-EB1645B0792AQ28388716-4144DE12-9332-48A4-8BC6-448F7E1710B5Q28954598-DB7B8590-B739-4B4D-8BFA-136288ADA29AQ29051494-C0AC247D-E393-41C6-B9AB-91894E6ED6E5Q29194011-72036801-CDA1-4A93-8450-E37D1F35CC47Q29274569-7A7EE68E-B514-42AA-8B07-DDC62471267EQ29571224-D877CAFE-565A-480B-8422-8A2542E8C405Q29994674-0060EF7C-A4FF-4A1C-AAC1-FD4F071EA77EQ30250907-DA826A80-F4B5-4CC9-9539-56305066DAE3Q33896995-B7FDC0D5-C137-465A-86A9-64E9C4095B91Q34481246-2A930CCF-98EB-494A-84A7-18CBCF473D21Q34615061-DB0F77A1-A304-4339-91B1-D154A3442454Q34885695-95F06357-E59B-480D-9C24-29727BC0B6B6Q35758626-A6143218-0365-497B-8815-573E14DFE763Q35957424-3C1388B0-A4B3-41D8-9EAA-89BA5DE9241FQ36265085-21A291BF-6AA5-439B-8F35-6419282C6339Q36267387-B5A5D44E-F621-4B9B-B2E0-5B06B3A863BCQ36341250-AC84B284-CF0A-4EF2-A0FC-28F7CA2095A0Q38359973-914520FF-5E3F-4134-BCB0-7BCE61D1309CQ38559337-9FAA06AD-81EC-4179-95B3-FC1E1E43DC37Q38586294-69D44D85-5E9D-4597-8803-784BEA756B60Q38761049-59DC1C49-F20E-4819-BD7B-7D3B374EFB13Q38869807-B331036D-9220-41C4-A5C3-73F59EE2A243Q39032355-E5D8C0DA-EF02-4EF4-B138-93019A7F66DAQ40049495-5976A91C-E7C7-4B96-B7C2-04604AF3C763Q40082484-DDA01CF9-23BA-4993-A300-6B4D5E942E01Q40203647-1E07C013-267E-40B4-8731-F3E63B81A51FQ40646400-0093A21E-FBED-4BC3-8D21-F4F97CBAB2C6Q46239950-447B41BA-B3F4-4172-9BC4-8EDCE0E65BD6Q47180730-254E8C94-CCA9-4A67-9C51-9D689B7DBB7CQ47551011-6AD783CD-3EDA-4D58-B814-9AE9EAB2141EQ48095971-F9AFC94C-E6B4-4897-B63E-0FEBEE733785Q50204408-DCB9EF31-E427-4D17-ACC4-211728C25308Q53686499-280A1E31-14B2-4C88-8046-73BC78870261Q55438581-8AB4ED9F-D4E8-4500-B339-4380FAD4F0C5
P2860
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and duration of immun ...... for a booster every 10 years.
@en
Efficacy and duration of immun ...... for a booster every 10 years.
@nl
type
label
Efficacy and duration of immun ...... for a booster every 10 years.
@en
Efficacy and duration of immun ...... for a booster every 10 years.
@nl
prefLabel
Efficacy and duration of immun ...... for a booster every 10 years.
@en
Efficacy and duration of immun ...... for a booster every 10 years.
@nl
P2860
P356
P1476
Efficacy and duration of immun ...... d for a booster every 10 years
@en
P2093
Eduardo Gotuzzo
Sergio Yactayo
P2860
P304
P356
10.4269/AJTMH.13-0264
P407
P577
2013-09-01T00:00:00Z